Get started
Author

Eduardo Munhoz

Observed names: EDUARDO CILIÃO MUNHOZ, Eduardo Cilião Munhoz, Eduardo C. Munhoz, Eduardo Ciliao Munhoz, Eduardo Cilião MUNHOZ, Eduardo Cilião Munhoz, MUNHOZ Eduardo Ciliao
OpenAlex ID: A5112835605
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
2022 · Lionel Adès, Larisa Girshova, et al. · Blood Advances · 134
PDF
Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study
2017 · Wojciech Jurczak, Ilídia Moreira, et al. · The Lancet Haematology · 83
Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma
2025 · Franck Morschhauser, Gilles Salles, et al. · Journal of Clinical Oncology · 57
PDF
Clinical assessment of oral mucositis and candidiasis compare to chemotherapic nadir in transplanted patients
2014 · PATUSSI Cleverson, SASSI Laurindo Moacir, et al. · Brazilian Oral Research · 29
PDF
Nilotinib dose‐optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENEST xtnd
2017 · Timothy P. Hughes, Eduardo Munhoz, et al. · British Journal of Haematology · 23
PDF
Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20-30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954)
2021 · Mikkael A. Sekeres, Larisa Girshova, et al. · Blood · 12
Fluorescent and colorimetric RT-LAMP as a rapid and specific qualitative method for chronic myeloid leukemia diagnosis
2021 · Anelis Maria Marin, Dalila Luciola Zanette, et al. · Analytical Biochemistry · 11
PDF
The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
2021 · Hervé Tilly, Franck Morschhauser, et al. · Blood · 10
Molecular BCR::ABL1 Quantification and ABL1 Mutation Detection as Essential Tools for the Clinical Management of Chronic Myeloid Leukemia Patients: Results from a Brazilian Single-Center Study
2023 · Anelis Maria Marin, Denise Kusma Wosniaki, et al. · International Journal of Molecular Sciences · 7
PDF
Divergent gene expression of PTGS1 and PTGS2 along the disease course of chronic myeloid leukaemia
2025 · Denise K. Wosniaki, Bianca N. Kusma, et al. · Frontiers in Oncology · 5
PDF
The Screening of microRNAs in Chronic Myeloid Leukemia: A Clinical Evaluation
2024 · Denise Kusma Wosniaki, Anelis Maria Marin, et al. · International Journal of Molecular Sciences · 4
PDF
Erratum: Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma
2025 · Franck Morschhauser, Gilles Salles, et al. · Journal of Clinical Oncology · 1
PDF
The importance of autologous stem cell transplant (ASCT) in multiple myeloma treatment in the lack of novel therapies
2025 · Natalia Cristina Rojas Guerrero, João Nunes, et al. · Blood · 1
PDF
Expression of HOTAIR and PTGS2 as potential biomarkers in chronic myeloid leukemia patients in Brazil
2024 · Ana Paula Kubaski Benevides, Anelis Maria Marin, et al. · Frontiers in Oncology · 1
PDF
Pancreatitis in adult with acute lymphoblastic leukemia using L-asparaginase and simvastatin: case report and systematic review
2016 · Renne Rodrigues, Diogo D. Gavarrete, et al. · Medicina (Ribeirão Preto) · 1
Efficacy and Safety of Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTxtnd Interim Analysis
2014 · Timothy P. Hughes, Eduardo Ciliao Munhoz, et al. · Blood · 1
Friday Leukemia: Senso Comum Posto a Prova
2026 · Luan Gabriel PINTO, João Samuel Holanda FARIAS, et al. · Hematology Transfusion and Cell Therapy
PDF
The Gab2 Network in Action: Unveiling Gab2, Grb2, Pik3r1, and Lyn in Chronic Myeloid Leukemia
2025 · Dalila Luciola Zanette, Denise Kusma Wosniaki, et al. · Hematology Transfusion and Cell Therapy
ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study
2022 · Christopher Flowers, Hervé Tilly, et al. · Clinical Lymphoma Myeloma & Leukemia
Oral Abstract: ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study
2022 · Christopher Flowers, Hervé Tilly, et al. · Clinical Lymphoma Myeloma & Leukemia
Poster: ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study
2022 · Christopher Flowers, Hervé Tilly, et al. · Clinical Lymphoma Myeloma & Leukemia
Avaliação da adesão ao mesilato de imatinibe de pacientes com leucemia mielóide crônica
2019 · ANABEL DE OLIVEIRA, EDUARDO CILIÃO MUNHOZ, et al. · Journal of Hospital Pharmacy and Health Services
PDF
Clinical assessment of oral mucositis and candidiasis compare to chemotherapic nadir in transplanted patients
2018 · PATUSSI Cleverson, SASSI Laurindo Moacir, et al. · Figshare
Works count: 23
Citation count: 380
H-index: 8
I10-index: 8
Year
Topic
Type